Funding to deliver key data in 2017
Mesoblast has raised US$40m (gross) through a placement of 26.25m shares at A$2.00/share. The cash enables continued funding of the key MPC-150-IM...
70 Views
Continued positive RA responses
Statistically significant area under the curve analysis from Mesoblast’s Phase II stem cell product in refractory rheumatoid arthritis (RA) shows...
59 Views
Longs & Shorts from Sohn Sydney Conference
With all the political excitement last week, the first Sohn Sydney conference on 11th November does not appear to have received much airtime within...
368 Views
Current Share Price Ascribes No Value to Chronic Heart Failure Potential, but Risk Still Very High
We maintain our risk-adjusted DCF-based fair value estimate for Mesoblast of A$6 per share and reiterate our no-moat and very high uncertainty...
190 Views
Mesoblast's Partner Receives Full Approval in Japan; Commercial Launch Ahead
Mesoblast's Japanese partner, JCR Pharmaceuticals, has received full approval from the Japanese Ministry of Health, Labour and Welfare for its...
283 Views